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Antibiotic resistance has become a major health issue. Nosocomial infections
and the prevalence of resistant pathogenic bacterial strains are rising steadily.
Therefore, there is an urgent need to develop new classes of antibiotics effective
on multi-resistant nosocomial pathogenic bacteria. We have previously shown that
a cell-permeable peptide derived from the p120 Ras GTPase-activating protein
(RasGAP), called TAT-RasGAP317−326, induces cancer cell death, inhibits metastatic
progression, and sensitizes tumor cells to various anti-cancer treatments in vitro
and in vivo. We here report that TAT-RasGAP317−326 also possesses antimicrobial
activity. In vitro, TAT-RasGAP317−326, but not mutated or truncated forms of the
peptide, efficiently killed a series of bacteria including Escherichia coli, Acinetobacter
baumannii, Staphylococcus aureus, and Pseudomonas aeruginosa. In vivo experiments
revealed that TAT-RasGAP317−326 protects mice from lethal E. coli-induced peritonitis
if administrated locally at the onset of infection. However, the protective effect was lost
when treatment was delayed, likely due to rapid clearance and inadequate biodistribution
of the peptide. Peptide modifications might overcome these shortcomings to increase
the in vivo efficacy of the compound in the context of the currently limited antimicrobial
options.
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INTRODUCTION
A first line of defense provided by the innate immune system of multicellular organisms relies
on the production of antimicrobial peptides. Since their initial discovery in the 1980s (Chan
et al., 2006), over 2,000 antimicrobial peptides have been isolated from virtually all classes of
living species, including humans, insects, plants, and bacteria themselves. Of interest, the peptide
gramicidin, isolated from Bacillus brevis by René Dubos in 1939, was the first antibiotic to
be commercially manufactured (Nakatsuji and Gallo, 2012). Usually, antimicrobial peptides are
composed of 10–50 amino-acid residues and classified into different categories based on their
amino-acid composition, size, and conformation (Nakatsuji and Gallo, 2012). They lack any
obvious specific consensus amino-acid sequences associated with biological activity; yet most of
them maintain certain common features, such as the presence of positively charged amino-acids
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or amphipathic nature. A majority of antimicrobial peptides
interact with the bacterial membrane, causing defects in
membrane integrity and ultimately inducing bacterial death
(Chan et al., 2006; Nakatsuji and Gallo, 2012). Various models
have been proposed to explain how given anti-bacterial peptides
negatively impact on bacterial membrane integrity, by the
formation of pores for example, but most of these models
remain to be experimentally validated (Chan et al., 2006). It is
now recognized that antimicrobial peptides can compromise
bacterial viability independently of their action on membrane
permeability, inhibiting for example protein or cell wall synthesis
(Guilhelmelli et al., 2013). Rather surprisingly, despite their
FIGURE 1 | TAT-RasGAP317−326, but not mutated or truncated forms, has antimicrobial activities. (A) Contaminated U2OS cell cultures treated or not with 20 µM
TAT-RasGAP317−326. Please observe the yellow color due to lower pH in presence of the growing contaminant. The contaminant was identified as Staphylococcus
capitis. The panel on the right shows the sensitivity of this isolate to the peptide. The bacteria were grown in the presence of the indicated concentrations of
TAT-RasGAP317−326. The OD 595 nm was measured after 16 h of incubation at 37
◦C. IC50, fifty percent maximal inhibitory concentration; MIC, Minimal inhibitory
concentration. (B) E. coli DH5α [optical density (OD) 600 nm of 0.25] were incubated for 7 h at 37◦C with the indicated concentrations of WT, mutated (W317A), or
truncated TAT-RasGAP317−326 (RasGAP317−326 and TAT-RasGAP317−319 ) peptides. The OD 600 nm was then measured. The results correspond to the mean ±
95% CI of three independent experiments. (C) E. coli DH5α (OD 600 nm of 0.25) were treated with 30 µM of different truncated versions of TAT-RasGAP317−326 for
7 h at 37◦C at which time bacterial density was recorded (OD 600 nm). White box represents a missing residue. Sequences highlighted in green allow at least 80%
decrease of OD 600 nm compared to untreated condition. Sequences highlighted in red do not inhibit E. coli growth. The results are derived from three independent
experiments. (D) E. coli DH5α (OD 600 nm of 0.25) were treated or not with 20 µM of TAT-RasGAP317−326 for the indicated periods of time at 37
◦C. Bacteria were
diluted in bacterial culture medium without peptide and colony forming units (CFUs) were determined on agar plates. The results correspond to the mean ± 95% CI of
three independent experiments. (E) E. coli DH5α (OD 600 nm of 0.25) were treated or not (NT) with 20 µM of TAT-RasGAP317−326 (TP) for 6 h at 37
◦C. The percent
of live cells was determined using LIVE/DEAD kit. The results correspond to the mean ± 95% CI of three independent experiments. (F) U2OS cells were incubated 3
days with the supernatant of a Mycoplasma hyorhinis-infected cell culture. Then, 30,000 cells were plated in a 6-well plate and 24 h later treated with 0, 20, and 40
µM of TAT-RasGAP317−326 for 3 additional days. The medium was then replaced with fresh peptide-containing medium and the cells incubated for 10 more days.
The supernatant of the culture was used to detect the presence of mycoplasma DNA by PCR as previously described (Uphoff and Drexler, 2005).
well-documented anti-bacterial properties, antimicrobial
peptides have poorly attracted the interest of antibiotic
producers that have rather focused on the development of
small synthetic anti-bacterial molecules. With the emergence
of antibiotic resistance against small antibiotic molecules
and the steady decline in the discovery and release of new
antibiotics, antimicrobial peptides hold the potential to provide
an alternative source of potent antimicrobial agents (Chan et al.,
2006).
TAT-RasGAP317−326 is a peptide composed of a cell permeable
moiety, the TAT HIV 48–57 sequence, and a 10 amino-acid
sequence derived from the Src Homology 3 Domain (SH3
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domain) of p120 RasGAP (Michod et al., 2004). This peptide
has various anticancer properties. It can sensitize tumor cells, but
not normal cells, to anticancer treatments, such as chemotherapy,
photodynamic therapy, and radiotherapy (Pittet et al., 2007;
Michod et al., 2009; Tsoutsou et al., 2017). It has anti-metastatic
properties by inhibiting cell migration and invasion (Barras et al.,
2013, 2014a). TAT-RasGAP317−326 also directly kills a subset of
cancer cells independently from apoptosis, necroptosis, and other
forms of regulated death (Heulot et al., 2016). In this study,
we uncovered an antimicrobial effect of TAT-RasGAP317−326.
We show that this peptide can efficiently kill a broad spectrum
of bacterial species in vitro. This peptide also confers efficient
protection in a mouse model of peritonitis caused by Escherichia
coli when administrated at the onset of infection.
RESULTS
TAT-RasGAP317−326 Possesses
Antimicrobial Activities
During an episode of contamination of mammalian cell cultures,
we observed that the growth of an initially uncharacterized
microorganism (later identified by sequencing as Staphylococcus
capitis) was prevented when the culture medium contained
the TAT-RasGAP317−326 peptide (Figure 1A). To extend this
observation, E. coli DH5α were incubated with wild-type (WT),
mutated (W317A), or a version of the peptide lacking the TAT
cell permeable sequence. The W317A mutant peptide is known
to be devoid of killing activity on eukaryotic cells (Heulot et al.,
2016). As shown in Figure 1B, TAT-RasGAP317−326, but not the
mutated or the TAT-deleted forms, prevented bacterial growth.
Several additional N-terminal and C-terminal truncated versions
of TAT-RasGAP317−326 were then tested. Figure 1C shows that
removing up to two residues from either the N-terminus or the
C-terminus did not abrogate the antimicrobial property of the
peptides. In contrast, the antimicrobial activity was lost when
four amino-acids or more were removed from either the N- or
the C-terminus.
To determine if the peptide has a bactericidal or bacteriostatic
effect, colony formation assays were performed. This allowed
estimating the number of remaining viable and proliferation-
proficient bacteria after peptide treatment. Figure 1D shows that
the ability of E. coli DH5α to form colonies was reduced by
more than one thousand fold after treatment with the peptide
for 6 h. Moreover, bacterial membrane integrity, assessed by
SYTO 9/propidium iodide staining, was greatly reduced after
6 h of peptide treatment, supporting the notion that TAT-
RasGAP317−326 is bactericidal (Figure 1E).
To determine if the peptide targets intracellular bacteria, we
tested its effect on a mammalian cell line contaminated with
Mycoplasma hyorhinis. Mycoplasma are eukaryote commensals
and can cause severe pathologies in humans (Uphoff andDrexler,
2005; Myers et al., 2010; Pascual et al., 2010). As shown in
Figure 1F, the peptide efficiently cleared mycoplasma from
infected eukaryote cell cultures.
TAT-RasGAP317−326-Mediated Growth
Inhibition of Potentially Pathogenic
Bacteria
To evaluate the spectrum of action of TAT-RasGAP317−326,
its antimicrobial activity was assessed in vitro on several
FIGURE 2 | TAT-RasGAP317−326-mediated growth inhibition of ATCC bacteria. The indicated bacteria strains obtained from ATCC were grown in appropriate media
in the presence of the indicated concentrations of TAT-RasGAP317−326. The OD 595 nm was measured after 16 h of incubation at 37
◦C. IC50, fifty percent maximal
inhibitory concentration; MIC, Minimal inhibitory concentration.
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bacterial species that are potentially harmful to humans
(listed in Table 1; their antibiotic sensitivity reported in
Table 2). Figure 2 reports data obtained with bacterial strains
originating from the ATCC collection. It shows that the
growth of Acinetobacter baumannii, E. coli, Pseudomonas
aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae
was reduced in the presence of the peptide. Burkholderia
cepacia, Klebsiella pneumoniae, and Serratia marcescens were
not, or only partially, affected by TAT-RasGAP317−326. We
then investigated the activity of the peptide on clinical isolates
of various microbes. Figure 3 shows that the RasGAP-derived
peptide inhibited the growth of patient-derived Enterococcus
faecium, E. coli, Listeria monocytogenes, P. aeruginosa, Salmonella
typhimurium, S. aureus, Stenotrophomonas maltophilia, and
Streptococcus pyogenes. The yeast Candida albicans and the
bacteria K. pneumoniae were not or poorly affected by TAT-
RasGAP317−326. To determine whether the peptide was effective
on multi-resistant bacteria, three independent clinical isolates of
Acinetobacter baumanii and P. aeruginosa resistant to several
classes of antibiotics (Table 3) were tested (Figure 4). The growth
of all isolates ofAcinetobacter baumaniiwas efficiently blocked by
the peptide, while the growth of only two isolates of P. aeruginosa
was inhibited and with lesser potency.
These data demonstrate that TAT-RasGAP317−326 has the
ability to target both pathogenic Gram-positive and Gram-
negative bacteria in vitro, some of which with pronounced
resistance to multiple antibiotics used in the clinic. Of note, B.
cepacia and S. marcescens, known to be naturally resistant to
antimicrobial peptides, as well as to polymixins (Olaitan et al.,
2014), an antibiotic class used as the last treatment option to
disrupt both the outer and inner membranes of Gram-negative
organisms (Yuan and Tam, 2008), were found also resistant, at
least partially, to the peptide (Figure 2).
TAT-RasGAP317−326 Neither Alters Mouse
Health Nor Triggers Hemolysis
If TAT-RasGAP317−326 is to be used clinically, it has to
display minimal cytotoxic activity in vivo. To address
that point, a third of the mouse lethal peptide dose was
injected twice a week for up to 6 months in BALB/c and
NMRI nude mice (Michod et al., 2009). This treatment
FIGURE 3 | TAT-RasGAP317−326-mediated growth inhibition of pathogenic clinical strains. The indicated bacteria isolates were grown in presence of the indicated
concentrations of TAT-RasGAP317−326. The OD 595 nm was measured after 16 h of incubation at 37
◦C. IC50, fifty percent maximal inhibitory concentration; MIC,
Minimal inhibitory concentration.
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FIGURE 4 | Effect of TAT-RasGAP317−326 on multi-drug resistant
Acinetobacter baumannii and Pseudomonas aeruginosa. The indicated
isolates were grown in the presence of the indicated concentrations of
TAT-RasGAP317−326. The OD 595 nm was measured after 16 h of incubation
at 37◦C. IC50, fifty percent maximal inhibitory concentration; MIC, Minimal
inhibitory concentration. The results were derived from two different
experiments (the data from each experiment labeled with a different color).
did not induce any deleterious effect or signs of distress
in mice and it did not affect their growth and weight gain
(Figures 5A,B). Moreover, inspection of organ sections (heart,
lung, kidney, liver, thymus, spleen, pancreas, salivary gland,
brain, stomach, small intestine, colon, uterus, ovary, fallopian
tubes, tongue, skin, eyes, spine, and femur) did not reveal
any difference between control and peptide injected groups.
Additionally, the peptide displayed no hemolytic activity even at
the highest dose tested (256µg/ml≈ 90µM; Figure 5C). Overall,
TAT-RasGAP317−326 seems not to displaymajor adverse effects in
vivo. There is therefore a potential therapeutic window for its use
as an antimicrobial agent.
TAT-RasGAP317−326 Can Protect from
E. coli Peritonitis
Finally, we explored the antimicrobial and protective capacity
of TAT-RasGAP317−326 in a mouse model of lethal peritonitis
FIGURE 5 | TAT-RasGAP317−326 does not alter mice health and does not
trigger hemolysis. The indicated number of 8-week-old BALB/c and NMRI
nude mice were i.p. injected twice a week with PBS or 1.6mg/kg
TAT-RasGAP317−326 (in PBS), weighed and evaluated for behavior and
general aspect. After 90 days, three mice per group were sacrificed for organ
inspection (A) Weight. The results correspond to the mean ± 95% CI. (B)
General aspect and behavior score (see Section Materials and Methods). A
score of 8 represents the limit above which mice need to be culled.
(C) Hemolysis activity was determined by treating human red blood cells with
various concentrations of TAT-RasGAP317−326. After 30min incubation at
37◦C, sample tubes were centrifuged and the absorbance of the supernatant
was measured at 540 nm. Maximum hemolysis (set at 100%) was triggered
with 0.5 % triton-X treatment of erythrocytes.
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FIGURE 6 | TAT-RasGAP317−326 can protect from E. coli peritonitis. (A–D) BALB/c mice (10 per group) were injected i.p. with 1.1 × 10
5 CFU E. coli O18 and 2min
(A,B) or 2 h later (C,D) with PBS, 1 mg/kg TAT-RasGAP317−326 or 4mg/kg ceftriaxone. (A,C) Survival of mice. (B,D) Bacterial counts in the blood 24 h post-infection.
The green dashed line indicates the limit of detection.
induced by E. coli O18 (Roger et al., 2009). Intraperitoneal
(i.p.) administration of 1 mg/kg TAT-RasGAP317−326 2 min
after an i.p. injection of E. coli significantly increased survival
rate from 20% (PBS control group) to 80% (Figure 6A), and
markedly reduced the number of circulating bacteria 24 h post-
infection (Figure 6B). The survival benefit was lost when the
peptide was injected 2 h after E. coli (Figure 6C). In these
conditions, no decrease in circulating bacteria was observed
(Figure 6D). In contrast, mice treated with ceftriaxone (a broad-
spectrum cephalosporin antibiotic) 2 h post-infection survived
E. coli peritonitis and had no detectable bacteria in their
blood. Taken together, these results demonstrate that, even if
TAT-RasGAP317−326 possesses a broad-spectrum antimicrobial
activity in vitro, its efficacy in vivo might be limited by factors
such as inefficient biodistribution and rapid clearance (Michod
et al., 2009).
DISCUSSION
Infections due to multi-resistant Gram-negative bacteria
encoding extended spectrum beta-lactamase (ESBLs) and
carbapenemases or Gram-positive bacteria such as methicillin
resistant S. aureus and vancomycin-resistant enterococci among
others, represent a very important public health challenge.
The emergence of drug-resistant bacteria is expected to be
only marginally prevented by active infection control (Kaspar
et al., 2015; Morris et al., 2016). Thus, there is an urgent need
for new antimicrobial agents to treat the increasing numbers
of patients suffering from life-threatening infections due to
multi-drug resistant Gram-negative and Gram-positive bacteria.
Novel active antimicrobial compounds can be obtained from
various sources including uncultured bacteria (Ling et al., 2015),
human microbiota (Zipperer et al., 2016) or plant extracts
(Tiwari et al., 2015, 2016) or they can be derived from known
proteins such as the TAT-RasGAP317−326 peptide used in this
study. We have uncovered in the present work that this peptide,
previously shown to bear various anticancer properties, is an
efficient antimicrobial agent toward a variety of pathogenic
bacterial species in vitro (Figures 2–4). This substantiates a
series of studies demonstrating that natural and synthetic
antimicrobial peptides exhibit a broad spectrum of cytotoxic
activity against cancer cells (Hoskin and Ramamoorthy,
2008; Riedl et al., 2011; Gaspar et al., 2013). Peptides with
dual antimicrobial and anticancer activities often act via the
disruption of bacterial and cancer cell membranes, such as
the bovine BMAP-28 peptide (Risso et al., 2002) and melittin
from bee venom (van den Bogaart et al., 2008). Their mode
of action is generally not well-characterized and, in some
cases, debated (Brogden, 2005). Lactoferricin B, for instance,
was first reported to exert its antimicrobial and antitumoral
activities via a pore-forming mechanism (Hwang et al., 1998;
Eliassen et al., 2006). Other reports mention that lactoferricin
B cytotoxicity is due to intracellular signaling perturbation in
microbial and mammalian cells (Mader et al., 2005; Tu et al.,
2011). We recently demonstrated that TAT-RasGAP317−326 kills
some cancer cells in a caspase-, apoptosis-, and necroptosis-
independent manner (Heulot et al., 2016). This raises the
possibility that TAT-RasGAP317−326 exerts a lytic activity
against certain cancer cells, potentially via membrane pore
formation. TAT-RasGAP317−326, as many antimicrobial
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FIGURE 7 | Biodistribution of I125-radiolabeled TAT-RasGAP317−326 in
BALB/c mice. Five BALB/c mice were injected with 1.6 mg/kg
I125-radiolabeled TAT-RasGAP317−326 peptide. Six hours after, mice were
sacrificed and radioactivity of each organ mentioned in the figure was
recorded in counts per minute (cpm). (A) Radioactivity of each organ
normalized per gram of organ. Carcass was all the remaining mouse material
after organ removal. Error bars are displayed in 95 percent confidence interval.
(B) Percentage of the injected radioactive dose recorded in each organ. Error
bars are displayed in 95 percent confidence interval.
peptides, contains arginine and tryptophan residues (Reddy
et al., 2004; Chan et al., 2006). Here, we show that substituting
the tryptophan at position 317 by alanine completely abrogates
the antimicrobial activity of the peptide in vitro (Figure 1B).
Noteworthy, this key residue was previously reported to be
crucial for all anticancer activities of the peptide (Barras
et al., 2014b; Heulot et al., 2016). To date, the mode of action
of TAT-RasGAP317−326 as an antimicrobial agent remains
unknown.
TAT-RasGAP317−326 protected against E. coli-induced
peritonitis when administered at the onset of infection. A
2-h delayed peptide injection did not prevent the spread of
infection. This could potentially be due to inadequate peptide
bio-distribution. Previous data reported that 1 h after i.p.
injection, there is a peak of TAT-RasGAP317−326 concentration
(of about 1 µM) in the blood that reached undetectable levels 2
h after injection (Michod et al., 2009). In addition, data obtained
6 h after i.p. injection with a radiolabeled version of the peptide
TABLE 1 | Strains used in this study.
Strain Used in Notes
Escherichia coli DH5α Figure 1
Staphylococcus capitis Figure 1 Mammalian cell
culture
contaminant
ATCC number
Acinetobacter baumannii Figure 2 19606
Burkholderia cepacia Figure 2 25416 Polymyxine-
resistant
Escherichia coli Figure 2 25922
Klebsiella pneumoniae Figure 2 27736
Pseudomonas aeruginosa Figure 2 27853
Serratia marcescens Figure 2 8100 Polymyxine-
resistant
Staphylococcus aureus Figure 2 29213
Streptococcus pneumoniae Figure 2 49619
Clinical isolate #
Candida albicans Figure 3 5102
Enterococcus faecium Figure 3 2015 04201636
Escherichia coli Figures 3
and 5
O18:K1:H7
Klebsiella pneumoniae Figure 3 Caroli
Listeria monocytogenes Figure 3 10403s
Pseudomonas aeruginosa Figure 3 547
Salmonella typhimurium Figure 3 C5
Staphylococcus aureus Figure 3 7AW
Stenotrophomonas maltophilia Figure 3 2015 01100914
Streptococcus pyogenes Figure 3 H305
Acinetobacter baumanii Figure 4 3 different isolates Antibiotic
Pseudomonas aeruginosa Figure 4 3 different isolates resistance profile
shown in Table 3
All strains were cultured in Cation Adjusted Mueller-Hinton medium. In the case of
S. pneumoniae, this mediumwas complemented with 2.5% lysed horse blood. The strains
are listed alphabetically and according to their use in the figures.
revealed a preferential accumulation within the liver, kidneys,
stomach and pancreas and a high concentration in urines,
suggesting that the peptide is efficiently eliminated through
the kidneys (Figure 7). Possibly, the TAT-RasGAP317−326
peptide could have a better impact on E. coli cystitis and/or
pyelonephritis than on E. coli peritonitis. This could be tested
in the future using previously reported pyelonephritis rat
models (Glauser and Bonard, 1982). Presumably due to its
suboptimal biodistribution and rapid clearance, the native
version of the TAT-RasGAP317−326 peptide exhibits an efficient
antimicrobial activity only within a very narrow time window.
Biochemical modifications that improve its distribution and
maintenance in whole organisms might therefore enhance its
in vivo applicability. Finally, deciphering its mode of action
might help identify new candidate molecules in bacteria that can
be targeted for the development of novel potent antimicrobial
agents.
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TABLE 4 | Scoresheet used to assess the impact on the health and behavior of
experimentally treated mice.
Parameter Animal ID Score
Appearance Normal 0
General lack of grooming 1
Staring coat, ocular, and nasal discharge 2
Piloerection, hunched up 3
Food and water intake Normal 0
Uncertain, body weight loss <5% 1
Intake reduced: body weight loss 5–15% 2
No food or water intake 3
Natural behavior Normal 0
Minor changes 1
Less mobile and alert, isolated 2
Vocalization, self-mutilation, restless or still 3
Provoked behavior Normal 0
Minor depression or exaggerated response 1
Moderate change in expected behavior 2
Reacts violently, or very weak or pre-comatose 3
MATERIALS AND METHODS
Bacteria
The bacteria strains used in this study are described in Table 1.
Peptides
TAT-RasGAP317−326 is a retro-inverso peptide (i.e., synthesized
with D-amino-acids in the opposite direction compared to the
natural sequence). The TAT moiety corresponds to amino-acids
48–57 of the HIV TAT protein (RRRQRRKKRG) and the
RasGAP317−326 moiety corresponds to amino-acids 317–326
of the human RasGAP protein (DTRLNTVWMW). These
two moieties are separated by two glycine linker residues
in the TAT-Ras-GAP317−326 peptide. TAT-RasGAP317−326
(W317A) has the tryptophan at position 317 mutated into an
alanine. These peptides were synthesized at the department
of biochemistry, University of Lausanne, Switzerland, using
FMOC technology, purified by HPLC and tested by mass
spectrometry.
Cells and Mycoplasma
The U2OS human osteosarcoma cell line (ATCC R© HTB-
96TM) was cultured in DMEM (Invitrogen, ref. no. 61965)
supplemented with 10% heat-inactivated fetal bovine serum
(FBS; Invitrogen, ref. no. 10270-106) in 5% CO2 at 37
◦C.
We obtained these cells from a laboratory that does not
routinely screen for mycoplasma contamination. These cells were
analyzed for the presence of mycoplasma-specific sequences.
This was done by PCR amplification of supernatant of super
confluent cell cultures using primers able to amplifyMycoplasma,
Acholeplasma, Ureaplasma, and Spiroplasma (sense primer #519:
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GGG AGC AAA CAG GAT TAG ATA CCC T and anti-
sense primer #520: TGC ACC ATC TGT CAC TCT GTT AAC
CTC; van Kuppeveld et al., 1992). The obtained PCR product
was then sequenced and found to correspond to M. hyorhinis
sequences.
Inhibition of Bacterial Growth
Bacterial growth was tested by optical density (OD)
measurements. The laboratory strain DH5α transformed
with pcDNA3 was cultured at 37◦C in LB medium
containing 100 µg/mL ampicillin. Bacteria were seeded
at an OD 600 nm of 0.25 and treated with the indicated
concentrations of peptides. OD 600 nm was measured after 7 h of
incubation.
The clinically relevant strains were grown in cation-adjusted
Mueller-Hinton medium. OD 595 nm was measured at 16 h of
treatment with various concentrations of TAT-RasGAP317−326.
IC50 and MIC were determined as described (Leber, 2016).
Colony Formation Assay
E. coli DH5α transformed with pcDNA3 were cultured at 37◦C
in LB medium containing 100 µg/mL ampicillin. Bacteria were
seeded at OD 600 nm of 0.25 and treated with indicated
concentrations of peptide. After the indicated time periods, the
bacterial suspension was diluted (from 10−2 to 10−6) in fresh
medium and 100 µL plated on LB agar plate containing 100
µg/mL ampicillin. After overnight incubation at 37◦C, colonies
were counted.
Bacterial Viability
E. coli DH5α transformed with pcDNA3 were cultured at 37◦C
in LB medium containing 100 µg/mL ampicillin. Bacteria were
seeded at OD 600 nm of 0.25 and treated or not with 20 µM
TAT-RasGAP317−326 for 6 h. Bacterial viability was assessed with
LIVE/DEAD BacLight Bacterial viability kit (Molecular Probes,
ref. no. L7012) according to manufacturer’s instructions using
Cytation3 (BioTek, ref. no CYT3MV) as a microplate reader.
Hemolytic Activity
Hemolytic activity was measured as described in Ando et al.
(2010). Briefly, blood (2 mL), derived from anonymous
healthy human blood donors obtained through the Vaud
blood transfusion service, were mixed with 2 mL PBS
and centrifuged at 800 g for 5 min at 4◦C. Samples
were washed three times with PBS and resuspended in
2 mL PBS and further diluted with 18 mL PBS. This
erythrocyte solution was diluted 10 times with PBS before
treatment with various amounts of TAT-RasGAP317−326
peptide. After 30min incubation at 37◦C, samples were
centrifuged at 800 g for 5min at 4◦C and the absorbance
at 540 nm of the supernatant was measured. As a
positive control (100% lysis), erythrocytes (200µL of
the final dilution preparation) were treated with 0.5%
Triton X-100.
In vivo Toxicity Assessment
Five-week-old NMRI nude and BALB/c mice (Charles River
Laboratories) were injected i.p. with PBS only or with 1.6mg/kg
of TAT-RasGAP317−326 diluted in PBS every Monday and
Thursday during 6months. Body weight as well as behavioral and
general aspect parameters (appearance, food and water intake,
natural behavior, provoked behavior) were monitored according
to FELASA recommendations (Table 4).
Mouse Models of Infections
BALB/cByJ mice (8–10 week-old females; Charles River
Laboratories) were weighed and randomly distributed into
groups of 9–10 animals of equal mean body weight. Mice were
injected i.p. with 1.1 × 105 CFU E. coli O18 (Ciarlo et al., 2016).
Two minutes after bacterial challenge, mice were injected i.p.
with PBS, TAT-RasGAP317−326 diluted in PBS or ceftriaxone as
described in the figure legends. Mice were monitored at least
twice daily to register severity scores, body weight, and survival
as described (Roger et al., 2013). Blood samples were harvested
from the facial vein for quantification of circulating bacteria.
Survival curves were generated using the Kaplan-Meier method
and differences were analyzed by the log-rank sum test. Statistical
differences for bacterial blood counts were assessed using the
non-parametric Mann–Whitney test. Analyses were performed
using PRISM (GraphPad Software). All reported P-values are
two-sided and values of <0.05 were considered to indicate
statistical significance.
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